TDM 105795
Alternative Names: CU 40101-101; CU-40101; TDM-105795Latest Information Update: 04 Oct 2024
At a glance
- Originator TechnoDerma Medicines
- Developer Cutia Therapeutics; TechnoDerma Medicines
- Class Skin disorder therapies; Small molecules
- Mechanism of Action Thyroid hormone receptor agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase II Alopecia
Most Recent Events
- 22 Feb 2024 Cutia Therapeutics completes a phase-I clinical trials in Alopecia in China (Topical) (NCT05380427)
- 05 Feb 2024 Adverse events and pharmacokinetic data from a phase IIa trial in Alopecia released by TechnoDerma medicines
- 05 Feb 2024 TechnoDerma medicines completes a phase IIa trial in Alopecia in USA (Topical)